Analysis of 65 renal biopsies from patients with rheumatoid arthritis (1976-2015): Change in treatment strategies decreased frequency and modified histopathological findings

Journal of Clinical Rheumatology

Volumn 21, Issue 7, 2015, Pages 335-340

  Vinicki, Juan P ^a   Pellet, Santiago C ^a   De Rosa, Graciela ^b   Dubinsky, Diana ^a   Laborde, Hugo A ^a   Marini, Alicia ^b   Nasswetter, Gustavo ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

abatacept; Anti TNF; Biologic therapy; D penicillamine; Gold salts; Methotrexate; Renal biopsies; Renal dysfunction; Rheumatoid arthritis; Rituximab; Tocilizumab; Urinary abnormalities

Indexed keywords

ABATACEPT; CORTICOSTEROID; GOLD SALT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; ANTIRHEUMATIC AGENT;

ADRIAMYCIN-INDUCED NEPHROPATHY; ADULT; AGED; ARGENTINA; FEMALE; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERSTITIAL NEPHRITIS; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; SOUTH AND CENTRAL AMERICA; TREATMENT INDICATION; ADOLESCENT; ARTHRITIS, RHEUMATOID; COMPLICATION; KIDNEY DISEASES; MIDDLE AGED; PATHOLOGY; RISK FACTOR; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARGENTINA; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84942517119     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000302     Document Type: Review

References (33)

1. Okuda Y, Takasugi K, Oyama T, et al. Amyloidosis in rheumatoid arthritis-clinical study of 124 histologically proven cases. Ryumachi. 1994;34:939-946.
2. Danila MI, Pons-Estel GJ, Zhang J, et al. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford). 2009;48:542-545.
3. Sellars L, Siamopoulos K, Wilkinson R, et al. Renal biopsy appearances in rheumatoid disease. Clin Nephrol. 1983;20:114-120.
4. Yoshinaga Y, Nishiya K, Yamamura M, et al. Study of urinary findings and renal functions in patients with rheumatoid arthritis (in Japanese). Kidney Dialysis. 1989;26:477-482.
5. Helin HJ, Korpela MM, Mustonen JT, et al. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum. 1995;38:242-247.
6. Nakano M, Ueno M, Nishi S, et al. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol. 1998;50:154-160.
7. Makino H, Yoshinaga Y, Yamasaki Y, et al. Renal involvement in rheumatoid arthritis: analysis of renal biopsy specimens from 100 patients. Mod Rheumatol. 2002;12:148-154.
8. Yoshida A, Morozumi K, Suganuma T, et al. Clinicopathological study of nephropathy in patients with rheumatoid arthritis. Ryumachi. 1991;31: 14-21.
9. Leonard PA, Bienz SR, Clegg DO, et al. Hematuria in patients with rheumatoid arthritis receiving gold and D-penicillamine. J Rheumatol. 1987;14:55-59.
10. Shankel SW, Johnson DC, Clark PS, et al. Acute renal failure and glomerulopathy caused by nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1992;152:986-990.
11. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
12. Geraldino-Pardilla L, Bathon JM. Management of rheumatoid arthritis: synovitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology, Sixth ed, Philadelphia: Elsevier Mosby; 2014: 853-859.
13. Smolen JS, Aletaha D, Koeller M, et al. New therapies for the treatment of rheumatoid arthritis. Lancet. 2007;370:1861-1874.
14. Myasoedova E, Crowson CS, Turesson C, et al. Incidence and mortality of extra-articular rheumatoid arthritis in Olmsted County, Minnesota, 1995-2007: a population based study. J Rheumatol. 2011;38:983-989.
15. Crowson CS, Hickson L, Gabriel SE, et al. Chronic kidney disease in rheumatoid arthritis. Arthritis Rheum. 2011;63:818-819.
16. Ramirez G, Lambert R, Bloomer HA. Renal pathology in patients with rheumatoid arthritis. Nephron. 1981;28:124-126.
17. Boers M, Croonen AM, Dijkmans BA, et al. Renal findings in rheumatoid arthritis: clinical aspects of 132 necropsies. Ann Rheum Dis. 1987;46: 658-663.
18. Lan HY, Nikolic-Paterson DJ, Zarama M, et al. Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. Kidney Int. 1993;43:479-485.
19. Hannum CH, Wilcox CJ, Arend WP. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibito. Nature. 1990;343:336-340.
20. Horii Y, Iwano M, Suematsu S, et al. Interleukin-6 and mesangial proliferation: generation and differentiation of IL-6 transgenic mice. In:. Sakai H, Sakai O, Nomoto Y, eds. Pathogenesis of IgA nephropathy. Japan: Harcourt Brace Javanovich; 1990;127-143.
21. Horii Y, Iwano M, Hirata E, et al. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int. 1993;43:S71-S75.
22. Dohi K, Iwano M, Muraguchi A, et al. The prognostic significance of urinary interleukin 6 in IgA nephropathy. Clin Nephrol. 1991;35:1-5.
23. Vinicki JP, De Rosa G, Laborde HA. Renal amyloidosis secondary to rheumatoid arthritis: remission of proteinuria and renal function improvement with tocilizumab. J Clin Rheumatol. 2013;19:211-213.
24. Egido J, Gómez-Chiarri M, Ortiz A, et al. Role of tumor necrosis factor-a in the pathogenesis of glomerular diseases. Kidney Int. 1993;43:S59-S64.
25. Ortiz A, Bustos C, Alonso J, et al. Role du tumor necrosis factor dans la pathogénie des glomerulonéphrites humaines et expérimentales. In: Actualités Néphrologiques, Hospitale Neker, ed. París: Actualités Néphrologiques; 1994; 51-75.
26. Korpela M, Mustonen J, Helin H, et al. Immunological comparison of patients with rheumatoid arthritis with and without nephropathy. Ann Rheum Dis. 1990;49:214-218.
27. Ogura T, Takaoka M, Ogata R, et al. Clinical study of renal injury by gold therapy in patients with rheumatoid arthritis (in Japanese). Jpn J Clin Immun. 1985;8:153-160.
28. Miyoshi A, Takaya Y, Kida K, et al. D-penicillamine nephropathy. J Clin Electron Microsc. 1980;13:55-62.
29. Nagakane T, Ogura T, Nishiya K, et al. Immuno-pathological study of bucillamine-induced nephropathy in patients with rheumatoid arthritis (in Japanese). Jpn J Clin Immunol. 1990;13:346-355.
30. Samuels B, Lee JC, Engleman EP, et al. Membranous nephropathy in patients with rheumatoid arthritis: relationship to gold therapy. Medicine. 1977;57:319-327.
31. Honkanen E, Toernroth T, Petterson E, et al. Membranous glomerulonephritis in rheumatoid arthritis not related to gold or D-penicillamine therapy: a report of four cases and review of the literature. Clin Nephrol. 1987;27:87-93.
32. Sennesael K, Houte VD, Verbeelen. Reversible membranous glomerulonephritis associated with ketoprofen. Clin Nephrol. 1986;26: 213-215.
33. Mustila A, Korpela M, Mustonen J, et al. Perinuclear antineutrophil cytoplasmic antibody in rheumatoid arthritis: a marker of severe disease with associated nephropathy. Arthritis Rheum. 1997; 40:710-717.